News
TAE Life Sciences Announces $40 Million In Venture Capital
2018 | Geekwire| Read Now
BNCT is a particularly promising technique for treating cancers of the head and neck region that are difficult or impossible to treat using other types of therapy. The procedure has already been tested in Japan, the United States and other locales.
TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A Funding
March 2018 | PR Newswire| Read Now
TAE Life Sciences is the first to license TAE Technologies’ accelerator-based neutron beam technology for clinical investigation of Boron Neutron Capture Therapy (BNCT).